摘要
目的评价西格列汀联合甘精胰岛素治疗2型糖尿病的有效性和安全性。方法将46例使用两种或两种以上口服降糖药物治疗血糖控制不佳的2型糖尿病患者随机分成西格列汀联合甘精胰岛素组(治疗组)23例和预混胰岛素组(对照组)23例,两组均以空腹血糖3.9～7.2mmol/L为控制目标,共治疗12周。观察治疗前、治疗12周后空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)及体重指数(BMI)的变化。结果治疗前后两组患者FPG、2hPG、HbA1c均较基线水平明显下降(P<0.001),两组间下降幅度差异无统计学意义(P>0.05),治疗组体重指数治疗前后无明显变化。对照组治疗后体重指数的增加与治疗前比较,差异有统计学意义(P<0.05)。治疗组低血糖事件的发生率低于对照组,(P<0.05)。结论与每日注射两次预混胰岛素比较,西格列汀联合睡前注射一次甘精胰岛素治疗口服降糖药物血糖控制不佳的2型糖尿病患者可使血糖得到良好控制,低血糖事件发生率低,治疗安全有效,而且依从性好。
Objective To evaluate the efficacy and safety of sitagliptin insulin glargine in the treatment of type 2 diabetes mellitus.Methods 46 patients with 2 or more oral hypoglycemic agent treatmented and unexpected efficacy,were randomly assigned to 2 groups： each group were 23 patients,Group A received sitagliptin insulin glargine,Group B received premix insulin.FPG 3.9-7.2mmol/L was the therapeutic goal after 12 weeks treatment.FPG,2hPG,Hba1c and BMI before and after 12 weeks were compred.Results After 12 weeks treatment,the levels of FPG,2HPG,HbA1c decreased significantly compared to baseline in both groups（P0.001）,and there was no significant difference between the 2 groups（P0.05）,BMI of sitagliptin group was no significant difference,BMI of premix insulin group was increased（P0.05）.Conclusions The method can reduce glycaemia frequency.and the treatment is safe and has good compliance.
出处
《四川医学》
CAS
2013年第6期824-826,共3页
Sichuan Medical Journal
